We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Wyeth's intravenous antibiotic Zosyn has reached blockbuster status despite not having patent protection, the company announced during its first-quarter earnings call. Read More
Merck is suing Teva Pharmaceutical to block the generic firm’s bid to market generic Singulair tablets, according to a lawsuit filed in federal court last week.
The U.S. Supreme Court will not make a determination on Ranbaxy’s challenge of the validity and enforceability of Pfizer’s main Lipitor patent, the court said this week.
IMPAX Laboratories has acknowledged the validity and enforceability of a key patent held by Purdue covering its pain treatment OxyContin, according to a settlement agreement reached by both companies.
Bristol-Myers Squibb (BMS) is cooperating with federal trade officials in a new civil probe launched last week related to the patent litigation settlement over generic Plavix, the company said.
The reinstatement of Merck’s Fosamax patent in Europe could spell trouble for generic firms who market their own versions of the
drug in that part of the world, according to A.G. Edwards & Sons.
The withdrawal of an antitrust lawsuit against Purdue Pharma concerning its pain treatment OxyContin is not expected to affect the company’s legal footing in other litigation, in which it remains confident it will prevail.